Viral News

Critical Analysis: Ritter Pharmaceuticals (NASDAQ:RTTR) & Adamis Pharmaceuticals (NASDAQ:ADMP)

Ritter Pharmaceuticals (NASDAQ:RTTR) and Adamis Pharmaceuticals (NASDAQ:ADMP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for Ritter Pharmaceuticals and Adamis Pharmaceuticals, as reported by

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ritter Pharmaceuticals0000N/A
Adamis Pharmaceuticals03102.25

Adamis Pharmaceuticals has a consensus target price of $1.30, suggesting a potential upside of 96.94%. Given Adamis Pharmaceuticals’ higher probable upside, analysts plainly believe Adamis Pharmaceuticals is more favorable than Ritter Pharmaceuticals.

Volatility & Risk

Ritter Pharmaceuticals has a beta of -0.43, indicating that its share price is 143% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500.

Valuation & Earnings

This table compares Ritter Pharmaceuticals and Adamis Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ritter PharmaceuticalsN/AN/A-$10.13 millionN/AN/A
Adamis Pharmaceuticals$22.11 million2.20-$29.31 million($0.55)-1.20

Ritter Pharmaceuticals has higher earnings, but lower revenue than Adamis Pharmaceuticals.

Insider & Institutional Ownership

0.8% of Ritter Pharmaceuticals shares are held by institutional investors. Comparatively, 15.7% of Adamis Pharmaceuticals shares are held by institutional investors. 15.4% of Ritter Pharmaceuticals shares are held by company insiders. Comparatively, 8.1% of Adamis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


This table compares Ritter Pharmaceuticals and Adamis Pharmaceuticals’ net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ritter PharmaceuticalsN/AN/A-162.05%
Adamis Pharmaceuticals-140.34%-76.02%-56.45%


Adamis Pharmaceuticals beats Ritter Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals logoRitter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company’s product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Adamis Pharmaceuticals Company Profile

Adamis Pharmaceuticals logoAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company’s specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men’s and women’s health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.

Receive News & Ratings for Ritter Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ritter Pharmaceuticals and related companies with’s FREE daily email newsletter.

Read More

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker